Aberrant expression of CD19 is associated with various B cell malignancies. Overexpression or constitutive activation of CD19 can lead to uncontrolled B cell proliferation and survival, contributing to the development of cancers such as CLL and B cell lymphomas. Conversely, loss of CD19 expression can impair B cell function and is sometimes observed in certain immunodeficiencies.
